CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
LYR-220 Design 1 (Part 1 only) +2 moredrug
Likely dose
LYR-220 Design 1 (Part 1 only) 7500 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05035654
NCT05035654Phase 2Completed
CompareCT.gov

BEACON: A Phase II, Patient-blinded, Two-part, Randomized, Parallel-group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LYR-220 in Chronic Rhinosinusitis (CRS) Patients Who Have Had a Prior Ethmoidectomy

Lyra Therapeutics·interventional·Posted Sep 5, 2021·Updated Dec 17, 2024

In Brief

A Phase 2 clinical trial evaluating LYR-220 Design 1 (Part 1 only), LYR-220 Design 2 (Part 1 and Part 2), and 1 other intervention for Chronic Sinusitis and Chronic Rhinosinusitis (Diagnosis). Completed, enrolled 48 participants across 25 sites in 2 countries.

Detailed Summary

This study will assess the safety, tolerability, pharmacokinetics and efficacy of two LYR-220 designs in symptomatic adult chronic rhinosinusitis (CRS) subjects who have had a prior functional endoscopic sinus surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
CountriesAustralia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedSep 5, 2021
Enrollment StartNov 23, 2021
Primary CompletionAug 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.8 years ago

Interventions

LYR-220 Design 1 (Part 1 only)drug

LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1

LYR-220 Design 2 (Part 1 and Part 2)drug

LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2

Bilateral sham procedure control (Part 2)drug

Bilateral sham procedure control